Real world data (RWD) company OM1 has announced $85 million in financing. The company uses RWD to develop personalized treatments for chronic diseases. OM1 is also developing artificial intelligence (AI) tools to predict patient outcomes. The company’s unique tools allow for streamlined regulatory approval and for payer decision-making.
OM1 Founder and CEO Dr. Richard Gliklich remarks, “There has been limited focus on using real-world data for autoimmune and other chronic conditions – despite those conditions representing more than $1.6 trillion in healthcare costs in the U.S alone,” adding, “With this funding, OM1 will expand our work building robust real-world data networks that are changing the research paradigm and enabling more precise treatments.” Read more here.
(Source: Cision PR Newswire, 7/16/21)